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Abstract This review article gives an overview on a
number of novel clinical trials and registries in the ﬁeld of
cardiovascular medicine. Key presentations made at the
75th annual meeting of the German Cardiac Society, held
in Mannheim, Germany, in April 2009 are reported. The
data were presented by leading experts in the ﬁeld with
relevant positions in the trials and registries. These com-
prehensive summaries should provide the readers with the
most recent data on diagnostic and therapeutic develop-
ments in cardiovascular medicine similar as previously
reported (Rosenkranz et al. in Clin Res Cardiol 96:457–
468, 9; Maier et al. in Clin Res Cardiol 97:356–363, 3).
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EuroCMR
Cardiovascular magnetic resonance (CMR) has a broad
range of clinical applications and is increasingly used in
daily clinical practice throughout Europe. Besides left
ventricular function, ischemia as well as myocardial tex-
ture can be investigated. During its German pilot phase the
EuroCMR registry sought to evaluate indications, image
quality, safety and impact on patient management of CMR
imaging in clinical routine in a large number of cases.
EuroCMR is a multicenter registry in which patients were
consecutively enrolled in 29 German CMR centers using
web based online case record forms. More than 10,000
patients were included in this ongoing registry between
June 2007 and January 2009. Image quality was found to
be good in 98% of cases. Severe complications occurred in
a minority of patients (\1%) and were all associated with
stress testing (using dobutamine or adenosine). However,
no patient died during or due to the CMR procedure. The
most often used reason to perform a CMR imaging (Fig. 1)
was myocarditis/cardiomyopathy (32%) followed by sus-
pected coronary heart disease or ischemia (31%), and
myocardial viability (15%). Case reading and reporting
were mostly done by cardiologists ([65%). In more than
half of the patients included (*60%) CMR ﬁndings
resulted in a change of patient management. Importantly, in
16% of cases, the ﬁnal diagnosis based on CMR was dif-
ferent to the diagnosis before CMR, leading to a complete
change in patient management. In 45% of the cases, no
further coronary angiography was needed after CMR. In
summary, CMR is frequently performed, seems safe, and
provides an important diagnostic tool with high image
quality leading to a great clinical impact. (Presenter:
O. Bruder, Essen)
FITT-STEMI
The purpose of the multicenter trial FITT-STEMI (Feed-
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assessment and systematic feedback improves treatment
times (i.e., contact-to-balloon time and door-to-balloon
time) and survival rates in patients with myocardial
infarction with ST-segment elevation (STEMI) [1]. For
many patients with STEMI, the time from presentation to
percutaneous coronary intervention (PCI) exceeds estab-
lished goals (\120 min ﬁrst medial contact-to-balloon
time). Till date, only registry data exist suggesting 26 more
deaths/1,000 patients for every 60 min that a PCI is
delayed (vs. 90 min contact-to-balloon time) in patients
with myocardial infarction. Formalized data feedback is
one strategy proposed to reduce treatment time in STEMI-
patients. The multicenter trial includes hospitals with pri-
mary PCI capacity (with currently two university clinics
and four additional hospitals). Existing protocols encour-
age prompt transfer of patients with STEMI to the PCI
center and emphasize minimizing time to treatment. In
each participating center, all patients presenting with
STEMI are enrolled (intention to treat). The study is con-
ducted prospectively during ﬁve consecutive 3-month
periods (quarters). Data collection is web-based and iden-
tical for the ﬁve quarters. For each center, the time points
from initial contact with the medical system to revascu-
larization are assessed, analyzed, and presented in an
interactive session to hospital and emergency services staff.
This formalized data feedback is performed at the end of
each quarter. Patients presenting during the ﬁrst 3-month
period are included as the reference group. Data from
patients with STEMI presenting during the next four
quarters are presented in the same manner. Having inclu-
ded more than 1,200 patients into the study, median con-
tact-to-balloon time could be reduced from 129 to 105 min
and door-to-balloon time from 70 to 50 min after 1 year.
Further analysis will show whether mortality can also be
decreased, especially in those patients with high TIMI risk
scores of 3–4 and especially C5 (Fig. 2). Since this is an
ongoing trial, other hospitals may participate additionally
in the near future. (Presenter: K. H. Scholz, Hildesheim)
IRIS
Implantable cardioverter deﬁbrillators (ICD) have been
shown to be effective for primary prevention of sudden
cardiac death in selected groups of patients in the chronic
phase after myocardial infarction. The IRIS (Immediate
Risk-Stratiﬁcation Improves Survival) study investigated
whether sudden cardiac death could be prevented in high
risk patients (EF B 40% and heart rate C 90/min or non-
sustained ventricular tachycardias (VTs) with heart
rates C 150/min) by ICD implantation\30 days after
myocardial infarction as compared to optimal medication
alone. Primary endpoint was death of all cause. 902
patients were randomized between June 1999 and October
2007. 76% of the patients were male, average EF was 34%.
Optimal medication consisted of antiplatelet therapy
(99%), b-blockers (90%), ACE-inhibitors (82%), and
statins. With respect to the primary endpoint, there was no
difference between both the groups over 72 months.
Therefore, the authors concluded that there is no evidence
that immediate (\30 days) ICD implantation after
myocardial infarction improves mortality. (Presenter:
D. Andresen, Berlin)
GERSHWIN
Percutaneous coronary intervention using sirolimus-
eluting stents (SES) has been shown to reduce in-
stent-restenosis compared to bare metal stents (BMS) [2].
The objective of the GERSHWIN (German stent health
outcome and economics within normal practice) study
was to study clinical beneﬁt (MACE: death, myocardial
infarction, bypass therapy, re-PCI in the target vessel),
costs, and quality of life using SES or BMS [3]. Patients
were allocated in a 2:1 fashion to SES or BMS from 2003
to 2005 in 35 centers across Germany. Cost calculation
was based on estimation of direct costs, including the
costs for stent implantation, rehabilitation, re-hospitaliza-
































Fig. 2 TIMI risk scores in patients included in FITT-STEMI
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123indirect costs involving disablement. Three-year follow-
up data were available for a total of 274 and 639 patients
treated with BMS or SES, respectively. After 3 years, re-
PCI in the target vessel was signiﬁcantly reduced from
23.3 to 16.6% in the SES compared to the BMS group
(relative risk reduction of 29%), while all other MACE,
as well as survival until ﬁrst MACE, did not differ sig-
niﬁcantly. As reported earlier, initial hospitalization costs
were 2,000 € lower in the BMS group, which was mainly
driven by stent costs. Direct follow-up costs were not
different between the groups, but indirect follow-up costs
were signiﬁcantly lower in the SES group (1,315 vs.
2,317 €). Total costs were slightly higher in the SES
group (17,494 vs. 16,295 €), resulting in 23,872 € for
each MACE to be avoided. Quality of life, which has
been signiﬁcantly better 3, 6, and 12 months after SES
implantation, was comparable between the two groups
36 months after implantation. In summary, SES leads to
signiﬁcantly less target vessel-revascularization proce-
dures compared to BMS. Total costs were still higher in
SES, whereas a decrease in follow-up costs did not
compensate for higher initial costs due to stent costs.
(Presenter: S. N. Willich, Berlin)
REGION: Regional differences in cardiac mortality
in Germany—results of a scientiﬁc evaluation
From 1998 until 2007, more than 2.3 million German
death records were manually encoded using WHO ICD-
10 classiﬁcation to compare regional patterns of cardiac
mortality. Importantly, patient age was standardized
according to the European standard population of 1976.
Death from ischemic heart diseases (ICD-10 I20-I25),
consisting largely of acute myocardial infarction (I20)
and chronic ischemic heart disease (I25) showed strong
regional variation with high ﬁgures ([155 cases per
100,000 men) in the north-east and the Saarland, and
\100 cases in the south, particularly in the south-west of
Germany. Figures for woman were generally only 50%
of those of men, with similar regional differences.
Regional variation did not change signiﬁcantly over time
(from 1998 to 2007) in men or women. However,
numbers of cardiac deaths decreased from 200 per
100,000 men in 1998 to 130 in 2007, and 100 per
100,000 women in 1998 to 70 in 2007. As a limitation,
manual coding of the death records is acknowledged. In
summary, a clear geographic gradient is found in cardiac
mortality, with a reduction in mortality of time. The data
can serve for further causal analyses. All-cause mortality
was similarly distributed, indicating socioeconomic fac-
tors to play a causal role in the regional variation.
(Presenter: S. N. Willich, Berlin)
SBK KardioPro
KardioPro (efﬁciently facing progression of coronary
artery disease by active risk management) is a prevention
study hypothesizing that early cardiovascular risk stratiﬁ-
cation (according to the PROCAM score) and optimal risk
factor management delay the onset of coronary artery
disease (CAD) and prevent severe courses of the disease.
Healthy insurance policy holders[45 years are subjected
to risk factor assessment and subsequent diagnostic tests
depending on the individual risk. In case of moderate or
high risk scores, non-invasive stress-testing is performed. If
CAD is suspected, the patients are subjected to coronary
angiography. Risk assessment is thoroughly discussed with
the participants, and individual advice particularly focusing
on life style changes is provided. Importantly, modern
cardiac diagnostic tools such as CT-angiography, perfu-
sion-MRT or stress-echocardiography have to be available
at the participating institutions. All participant visits are
documented electronically to build up a large coronary
prevention database. Until April 2009, 12,163 participants
at more than 80 centers have been included, of whom 70%
have been graded low risk, while CAD was diagnosed in
12%. Most of the participants (73%) were included into the
study in a preventive track, while 20% were suspected of
CAD and 7% had known CAD. CT-angiography was
particularly used in cases where risk factor assessment was
inconclusive. Coronary angiography was ﬁnally performed
in high risk situations including pathological non-invasive
tests. Evaluation of KardioPro with respect to clinical
endpoints will start in 2009. (Presenter: J. Brachmann,
Coburg)
OMEGA
Omega-3 fatty acids after myocardial infarction reduced
mortality in the GISSI-Prevenzione trial [4]. In the
OMEGA trial (randomized trial of omega-3 fatty acids on
top of modern therapy after acute myocardial infarction),
3,851 patients were treated with 1 g omega-3 fatty acids or
placebo from 3 to 14 days after myocardial infarction
(STEMI or NSTEMI) for 1 year in addition to optimal
medical therapy. In the course of the study, high-risk
patients ([70 years old, EF\40%, diabetics, lack of
revascularization) were selectively included, resulting in a
total of 24% of patients with an EF\40%. Around 90% of
all study patients were on optimal medical therapy fol-
lowing MI (aspirin, statin, betablocker, ACE-inhibitor).
The primary endpoint, sudden cardiac death, occurred in
1.5% of the patients in both the treatment and the placebo
group. Similarly, the secondary endpoints (major adverse
cardiac events and arrhythmic events, revascularization,
Clin Res Cardiol (2009) 98:413–419 415
123rehospitalization) did not differ between the groups.
Serum-triglycerides were signiﬁcantly decreased in the
treatment group (121 vs. 127 mg/dl). In summary, in
moderate to high-risk patients, strict guideline treatment is
associated with a very low risk of sudden cardiac death
(1.5%), which could not be further reduced by treatment
with omega-3 fatty acids. In contrast to the GISSI-Pre-
venzione trial, acute revascularization, clopidogrel, statin
and GPIIb/IIIa-antagonist treatment were more common in
the OMGA trial, which may explain the different ﬁndings
of the two studies. (Presenter: J. Senges, Ludwigshafen)
DHR
Of 1,082 German hospitals primarily treating ST-elevation
myocardial infarction (STEMI), 280 (26%) joined the DHR
(Deutsches Herzinfarkt Register) registry that aimed at
mirroring daily practice of MI treatment in Germany
without pre-selecting large or catheter laboratory equipped
institutions. More than 80% of all patients were revascu-
larized by primary PCI, only 5% by lysis therapy, while
10% of MI patients did not receive reperfusion therapy,
mostly because of the initial ECG was not interpreted as
acute STEMI or because of co-morbidities. In hospitals
with catheterization laboratory, the primary PCI was per-
formed in 90% and lysis in only 2%. Hospitals without
catheterization facilities performed lysis in 12% and
transferred for primary PCI in 70%. First medical contact
to balloon (i.e., revascularization by PCI), the time was
200 min if the patient was ﬁrst transferred to a hospital
without catheterization laboratory and 105 min if trans-
ferred to a center with catheterization facility. Fast treat-
ment of patients with MI decreased hospital mortality from
16.2% in 1994 to 6.8% in 2008 (Fig. 3a). At discharge,
more than 90% of the patients were treated according to
current guidelines, receiving aspirin, clopidogrel, statin,
betablocker, and ACE inhibitor. During the last 15 years,
the percentage of primary PCI in cardiogenic shock has
strongly risen from 16% in 1995 to almost 90% in 2008,
reducing mortality from 72 to 38% (Fig. 3b). In summary,
the DHR shows a high percentage of primary PCI in
myocardial infarction, a good adherence to the guidelines
concerning optimal medical therapy post MI, a low in-
hospital mortality but still high mortality in patients pre-
senting with cardiogenic shock. (Presenter: U. Zeymer,
Ludwigshafen)
Stem cells in AMI
In the past years, several studies have shown that intra-
coronary administration of bone marrow-derived progeni-
tor cells may have a beneﬁcial effect in cardiovascular
disease [5]. Improved left ventricular function in patients at
risk for adverse remodeling after acute myocardial infarc-
tion has been correlated with stem cell application. All
these studies had in common that recanalization therapy
and stem cell application were performed within the ﬁrst
hours during myocardial infarction. In this presented ran-
domized, double-blind, placebo-controlled trial, a total of
42 patients with myocardial infarction have been enrolled
at least 6 h after recanalization therapy. Only patients
with a creatine kinase[1,000 U/l were included. 29 of
these patients received bone-marrow-derived stem cells
(381 ± 130 9 10
6 mononuclear cells) and 13 received
placebo. By means of contrast-enhanced magnetic reso-
nance imaging (MRI), left ventricular volumes and EF
were determined at baseline and compared at 1, 3 and
6 months of follow-up. At all three investigated points of
time, no signiﬁcant improvement (P = 0.80) of the EF,
diameters of the left ventricle during diastole (LVEDD)
and systole (LVESD) or the size of myocardial scar tissue
could be observed. As these results lacked beneﬁt, this led
to the immediate stop of this study. (Presenter: J. Wo ¨hrle,
Ulm)
Heinz-Nixdorf Recall study
First serious cardiac events are often fatal, and half of all
CHD deathsare sudden coronarydeathsand occur outof the
hospital. Quantiﬁcation of subclinical atherosclerosis has
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AB Fig. 3 Decrease in hospital
mortality in STEMI (a) and
STEMI complicated by
cardiogenic shock (b)
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123beyond established risk factor assessment [6]. The pro-
spective cohort-study evaluated 4,137 patients (53%
women) without known coronary artery disease regarding
predictors and signs of subclinical atherosclerosis. The
patients were aged between 45 and 75 years and were
investigated from December 2000 until August 2003. The
areaofcoronaryarterycalciﬁcation(CAC)wasmeasuredby
Electronbeamtomography.CAC wasdeﬁned asatleast four
contiguous pixelswith a CTdensity C130 Hounsﬁeld Units.
The patient cohort was divided into three groups corre-
spondingtotheATPIIIcategory(low,intermediateandhigh
risk).The5-yearoutcomedatashowedthattheCAC-scoreis
a better predictor of cardiovascular disease compared to
classicalriskfactorssuchassmoking,hypertension,diabetes
or obesity. However, the risk prediction was more valid in
men than in women and is suggested to improve risk pre-
diction of patients, especially with intermediate risk.
Determination of CAC can be used for reclassiﬁcation of
persons with moderate stroke risk (10–20%) Beyond this,
patientswithlow-riskhavinga10-year-riskbelow10%have
no beneﬁt of this risk stratiﬁcation. (Presenter: R. Erbel,
Essen)
HIT
HIT (Herz im Takt) is a new concept based on a contract
between the university hospital of Schleswig-Holstein and
surgeries (cardiologists) improving medical treatment of
patients with coronary artery disease (CAD). The goal of all
partners of this contract was to improve the quality of life of
all patients with CAD and to prevent heart attacks. The
established cardiologist performed the ﬁrst outpatient
diagnosis and risk classiﬁcation, and then transferred the
patient to the university hospital where coronary angiog-
raphy could be performed. Afterwards, the patient was
discharged and continued treatment in care of his cardiol-
ogist. Through close coordination and interaction between
outpatient, inpatient and rehabilitative treatment double
examinations could be avoided and the patient had an
optimal quality of care offered. In consequence of this close
cooperation, a higher rate of intake of the prescribed med-
ication was shown which could be attributed to the study-
related compliance. Betablockers were shown to be taken in
76% of all cases after 1 year versus 65% at the beginning.
The next aim is to establish this contract-concept through-
out Germany. (Presenter: E. Schuhr, Hamburg)
DYSIS
The main known risk factors enhancing development
and progression of cardiovascular diseases are lifestyle,
obesity, hypertension, diabetes [7] and lipid disorders.
Large randomized studies have proved in the past, the
effectiveness of lipid lowering by statins. Since then, they
belong to standard therapy in the secondary and primary
prevention of cardiovascular disease. Nevertheless, many
patients do not reach the recommended lipid values [8].
DYSIS (Dyslipidemia International Study) is an interna-
tional, prospective register-study evaluating the prevalence
of persistent lipid disorders despite current medical therapy
with statins. From April 2008 to February 2009, a total of
22,063 patients with already ongoing statin therapy were
enclosed via 2,987 surgeries in 11 European countries and
Canada. Nearly half of the patients undergoing chronic
statin therapy did not reach the target levels for LDL-
cholesterol as recommended in the guidelines (Fig. 4).
Additionally, two-thirds of these patients had further
abnormal values for HDL-cholesterol or triglycerides. The
results of DYSIS demonstrate the discrepancy between
recommendations of professional societies and clinical
practice in the treatment of lipid disorders in terms of
primary and secondary prevention, and the potential for
improvements in medical treatment of the outpatient
belonging to the risk groups. (Presenter: A. K. Gitt,
Ludwigshafen)
US multicenter RCT of cardiac contractility
modulation in patients with advanced heart failure
(FIX-CHF-5)
Congestive heart failure (CHF) remains one of the most
frequent causes of morbidity and mortality. Despite major
advances in pharmacological therapy and/or device-based
treatment, millions of patients suffer from CHF with heart
failure symptoms NYHA III or IV and less than half of
these patients are eligible for resynchronization therapy.
A new approach with cardiac contractility modulation
(CCM) has been investigated in the FIX-CHF-4 study.
Here, it was shown that CCM treatment was associated
with clinically and statistically signiﬁcant improvements in
Fig. 4 Persistent lipid disorders with ongoing statin therapy in
correlation with the risk of cardiovascular complications
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123exercise tolerance and quality of life [9]. CCM signals are
intended to improve the strength of muscle contraction.
This new concept based on observations that electrical
impulses delivered to the right ventricular septum during
the heart’s absolute refractory period appear to enhance left
ventricular contractility without actually causing excita-
tion. The FIX-CHF-5 is a pivotal trial underway at 50 sites
in the United States. The FIX-CHF-5 study was a multi-
center, prospective, double-blind, crossover study con-
ducted in 428 patients with NYHA class III or IV [ejection
fraction (EF) B 35%] despite optimal therapy. All patients
had QRS complexes within normal limits and patients with
atrial ﬁbrillation were excluded. 95% of patients had an
implantable cardioverter-deﬁbrillator (ICD). Primary end
point was the anaerobic threshold (AT). Co-secondary
endpoints concernded exercise tolerance (peak VO2) and
quality of life. In the study design, all patients received a
device that was switched off at time of implantation to
ensure double blinding. After a 2-week run-in period, 215
patients had their device switched on, whereas 213 kept it
switched-off and received only medical treatment. Non-
excitatory impulses to the heart were delivered 5 h per day.
The safety endpoint of mortality and hospitalization after
12 months was not different in both groups. Moreover, the
primary efﬁcacy endpoint (anaerobic threshold) could not
be reached by most of the investigated patients and there-
fore could not be really taken into account in the results.
However, quality of life, NYHA classiﬁcation and VO2
signiﬁcantly (P\0.001, P = 0.0026 and P\0.024)
increased in patients with CCM compared to medical
treatment alone. Besides these ﬁndings, a subgroup anal-
ysis revealed a signiﬁcant beneﬁt regarding the primary
endpoint of AT in patients with an EF B 25% with NYHA
III (P = 0.04) and NYHA IV (P = 0.19). (Presenter: M.
Borggrefe, Mannheim)
SYNTAX
The SYNTAX (Synergy between percutaneous coronary
intervention with TAXUS and cardiac surgery) trial was an
international, multicenter, randomized, controlled com-
parison of coronary-artery bypass grafting (CABG) versus
PCI with drug-eluting stents in 1,800 patients with previ-
ously untreated three-vessel or left main coronary artery
disease (or both) [10]. The primary clinical end point was a
composite of major adverse cardiac and cerebrovascular
events (i.e., death from any cause, stroke, myocardial
infarction, or repeat revascularization). A noninferiority
comparison of the two groups demonstrated signiﬁcant
Fig. 5 Rates of outcomes among the study patients, according to
treatment group [10]. Kaplan–Meier curves are shown for the
percutaneous coronary intervention (PCI) group and the coronary-
artery bypass grafting (CABG) group for death from any cause (Panel
A); death, stroke, or myocardial infarction (MI) (Panel B); repeat
revascularization (Panel C); and the composite primary end point of
major adverse cardiac or cerebrovascular events (Panel D). The two
groups had similar rates of death from any cause (relative risk with
PCI vs. CABG, 1.24; 95% conﬁdence interval [CI], 0.78–1.98) and
rates of death from any cause, stroke, or MI (relative risk with PCI vs.
CABG, 1.00; 95% CI, 0.72–1.38). In contrast, the rate of repeat
revascularization was signiﬁcantly increased with PCI (relative risk,
2.29; 95% CI, 1.67–3.14), as was the overall rate of major adverse
cardiac or cerebrovascular events (relative risk, 1.44; 95% CI, 1.15–
1.81). The I bars indicate 1.5 SE. Relative risks were calculated from
the binary rates. P values were calculated with the use of the chi-
square test
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123higher rates of major adverse cardiac or cerebrovascular
events at 12 months in the PCI group (17.8 vs. 12.4% for
CABG, P\0.001). This result was driven by an increased
rate of repeat revascularization in the PCI group (13.5 vs.
5.9% for CABG, P\0.001). In an analysis of secondary
endpoints, the two groups had similar rates of death from
any cause or myocardial infarction and of the combined
end point of death from any cause, stroke, or myocardial
infarction (7.6% for PCI and 7.7% for CABG). The 12-
month rates of symptomatic graft occlusion (CABG group)
and stent thrombosis (PCI group) were similar (P\0.89).
Stroke was signiﬁcantly more likely to occur with CABG
(2.2 vs. 0.6% with PCI, P\0.003). The rate of major
adverse cardiac or cerebrovascular events among patients
with left main coronary artery disease was similar in the
CABG and PCI groups (13.7 and 15.8%, respectively,
P\0.44, see Fig. 5). To predict outcomes related to
anatomical characteristics, the SYNTAX score was
designed. Patients with low or intermediate SYNTAX
scores in the CABG and in the PCI group had similar rates
of major adverse cardiac or cerebrovascular events,
whereas among patients with high scores (indicating more
complex coronary anatomy), the event rate was signiﬁ-
cantly increased in the PCI group. Notable strengths and
limitations and clinical implications of the SYNTAX trial
were discussed by the presenters. Strengths: it was a pro-
spective, multicenter trial in which a large number of
patients were enrolled at 85 centers in Europe and the
United States. It attempted to include ‘‘all comers’’ with
left main or three-vessel coronary artery disease (or both)
with an impressively high enrollment rate (59% of all
screened, eligible patients were included). The study used
state-of-the-art CABG and PCI (with arterial grafts and
drug-eluting stents, respectively). Limitations: the follow-
up period was only 12 months; the outcomes of PCI and
CABG over a longer period of follow up in patients with
severe coronary artery disease are unknown. The primary
(composite) endpoint was driven by the revascularization
rate. With respect to hard endpoints (death from any cause
or myocardial infarction and the combined end point of
death from any cause, stroke, or myocardial infarction),
there was no signiﬁcant difference between the two groups.
But these endpoints were secondary endpoints with
observational character. All discussants agreed that in
patients with left main or three-vessel coronary artery
disease, all pertinent data, including that from diagnostic
angiography, should be reviewed by a team consisting of a
cardiac surgeon, and an interventional cardiologist to
determine the likelihood of safe and effective revasculari-
zation with PCI and CABG. The SYNTAX score, indi-
cating the complexity of the coronary anatomy, identiﬁes
patients with increased risk of a suboptimal outcome with
PCI. (Presenters: T. Meinertz, Hamburg; F. W. Mohr,
Leipzig; G. C. Schuler, Leipzig).
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